Free Trial

Pfizer (PFE) Stock Price, News & Analysis

Pfizer logo
$24.20 -0.04 (-0.18%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$24.18 -0.02 (-0.07%)
As of 06/27/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pfizer Stock (NYSE:PFE)

Key Stats

Today's Range
$24.08
$24.42
50-Day Range
$22.01
$24.85
52-Week Range
$20.92
$31.54
Volume
39.50 million shs
Average Volume
41.37 million shs
Market Capitalization
$137.56 billion
P/E Ratio
17.53
Dividend Yield
7.11%
Price Target
$29.17
Consensus Rating
Moderate Buy

Company Overview

Pfizer Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of medicines and vaccines. The company’s core activities span research and development, manufacturing, and marketing of products across a wide range of therapeutic areas. Pfizer’s portfolio addresses conditions in immunology, oncology, cardiology, endocrinology, rare diseases, neuroscience and infectious diseases, with a focus on delivering innovative treatments that improve patient outcomes.

Founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, Pfizer began as a fine-chemicals firm and soon expanded into large-scale pharmaceutical manufacturing. Over its history, the company has grown through a combination of internal R&D efforts and strategic acquisitions, including the 2009 purchase of Wyeth and the 2015 acquisition of Hospira. These moves strengthened its vaccine and sterile injectable businesses and broadened its therapeutic capabilities.

Today, Pfizer is known for its leading vaccines, such as the pneumococcal Prevnar franchise, and for breakthrough therapies in oncology, including Ibrance and Xtandi (the latter developed in collaboration with Astellas). The company’s research pipeline also features antiviral therapies, immuno-oncology candidates and precision medicines for genetic disorders. Collaboration with biotech partners and academia plays a central role in Pfizer’s innovation strategy, helping to advance early-stage science toward clinical development.

With commercial operations in more than 125 countries and research centers in the United States, Europe and Asia, Pfizer maintains a broad geographic footprint. Under the leadership of Chairman and CEO Albert Bourla, who took the helm in 2019, the company continues to prioritize investment in R&D, strategic alliances and sustainable manufacturing practices. Pfizer’s mission remains focused on leveraging scientific excellence to address global health challenges and deliver therapies that make a meaningful difference in patients’ lives.

AI Generated. May Contain Errors.

Pfizer Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

PFE MarketRank™: 

Pfizer scored higher than 97% of companies evaluated by MarketBeat, and ranked 33rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pfizer has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 3 buy ratings, 8 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Pfizer has only been the subject of 3 research reports in the past 90 days.

  • Read more about Pfizer's stock forecast and price target.
  • Earnings Growth

    Earnings for Pfizer are expected to grow by 2.71% in the coming year, from $2.95 to $3.03 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pfizer is 17.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.00.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pfizer is 17.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.15.

  • Price to Earnings Growth Ratio

    Pfizer has a PEG Ratio of 0.88. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Pfizer has a P/B Ratio of 1.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Pfizer's valuation and earnings.
  • Percentage of Shares Shorted

    1.88% of the float of Pfizer has been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 1.66%, indicating that investor sentiment is decreasing.
  • Dividend Leadership

    Pfizer is a leading dividend payer. It pays a dividend yield of 7.11%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Pfizer has been increasing its dividend for 16 years.

  • Dividend Coverage

    The dividend payout ratio of Pfizer is 124.64%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Dividend Sustainability

    Based on earnings estimates, Pfizer will have a dividend payout ratio of 56.77% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

  • Read more about Pfizer's dividend.
  • Percentage of Shares Shorted

    1.88% of the float of Pfizer has been sold short.
  • Short Interest Ratio / Days to Cover

    Pfizer has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pfizer has recently increased by 1.66%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Pfizer has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 81 news articles for Pfizer this week, compared to 64 articles on an average week.
  • Search Interest

    Only 160 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
  • MarketBeat Follows

    Only 53 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pfizer insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.06% of the stock of Pfizer is held by insiders.

  • Percentage Held by Institutions

    68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Pfizer's insider trading history.
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

PFE Stock Analysis - Frequently Asked Questions

Pfizer's stock was trading at $26.53 at the beginning of the year. Since then, PFE stock has decreased by 8.8% and is now trading at $24.1960.
View the best growth stocks for 2025 here
.

Pfizer Inc. (NYSE:PFE) announced its quarterly earnings results on Tuesday, April, 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer's revenue for the quarter was down 7.8% on a year-over-year basis.
Read the conference call transcript
.

Pfizer subsidiaries include these companies: ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and more.

Top institutional investors of Pfizer include Vanguard Group Inc. (9.22%), Wellington Management Group LLP (1.82%), Massachusetts Financial Services Co. MA (1.33%) and Northern Trust Corp (1.10%). Insiders that own company stock include Pfizer Inc, Ronald E Blaylock and Scott Gottlieb.
View institutional ownership trends
.

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include Scilex (SCLX), Salesforce (CRM), Chevron (CVX), AbbVie (ABBV), Johnson & Johnson (JNJ), Meta Platforms (META) and Bristol Myers Squibb (BMY).

Company Calendar

Last Earnings
4/29/2025
Record date for 6/13 Dividend
5/09/2025
Ex-Dividend for 6/13 Dividend
5/09/2025
Dividend Payable
6/13/2025
Today
6/29/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Large Cap Pharma
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:PFE
Employees
81,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$29.17
High Stock Price Target
$34.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+20.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Trailing P/E Ratio
17.53
Forward P/E Ratio
8.20
P/E Growth
0.88
Net Income
$8.03 billion
Pretax Margin
11.83%

Debt

Sales & Book Value

Annual Sales
$63.63 billion
Cash Flow
$4.37 per share
Price / Cash Flow
5.54
Book Value
$15.62 per share
Price / Book
1.55

Miscellaneous

Outstanding Shares
5,685,370,000
Free Float
5,681,955,000
Market Cap
$137.56 billion
Optionable
Optionable
Beta
0.57

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NYSE:PFE) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners